AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 101 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2023. The put-call ratio across all filers is 0.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $188,686 | -37.3% | 18,319 | +0.4% | 0.00% | – |
| Q2 2023 | $300,760 | +79.9% | 18,250 | 0.0% | 0.00% | – |
| Q1 2023 | $167,170 | +27.9% | 18,250 | 0.0% | 0.00% | – |
| Q4 2022 | $130,670 | +1206.7% | 18,250 | +808.0% | 0.00% | – |
| Q3 2022 | $10,000 | +233.3% | 2,010 | +518.5% | 0.00% | – |
| Q4 2021 | $3,000 | +200.0% | 325 | -10.7% | 0.00% | – |
| Q3 2019 | $1,000 | -94.4% | 364 | -97.1% | 0.00% | – |
| Q1 2019 | $18,000 | -43.8% | 12,500 | 0.0% | 0.00% | – |
| Q4 2018 | $32,000 | -41.8% | 12,500 | 0.0% | 0.00% | – |
| Q3 2018 | $55,000 | -28.6% | 12,500 | 0.0% | 0.00% | – |
| Q2 2018 | $77,000 | -15.4% | 12,500 | 0.0% | 0.00% | – |
| Q1 2018 | $91,000 | -11.7% | 12,500 | 0.0% | 0.00% | – |
| Q4 2017 | $103,000 | -21.4% | 12,500 | 0.0% | 0.00% | – |
| Q3 2017 | $131,000 | -5.1% | 12,500 | 0.0% | 0.00% | – |
| Q2 2017 | $138,000 | +14.0% | 12,500 | 0.0% | 0.00% | – |
| Q1 2017 | $121,000 | – | 12,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
| Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
| JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
| ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
| FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
| KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
| Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
| Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
| HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |